TTFields plus modFOLFIRINOX for metastatic pancreatic adenocarcinoma

Phase Ib-II, Non-randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With modFOLFIRINOX for Front-line Treatment of Metastatic Pancreatic Adenocarcinoma (NOVOFFOX)

This trial will test whether adding Tumor Treating Fields (TTFields) to modFOLFIRINOX chemotherapy is safe, tolerable, and helpful for adults with metastatic pancreatic ductal adenocarcinoma.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Clinica Universidad de Navarra, Universidad de Navarra (Academic / other)
• Drugs / interventions: chemotherapy, radiation, immunotherapy
• Locations: 5 sites (Pamplona, Navarre and 4 other locations)
• Trial ID: NCT07284277 on ClinicalTrials.gov

What this trial studies

This is a phase Ib–II, open-label, non-randomized, single-arm, multi-center study combining the NovoTTF-200T system with modFOLFIRINOX in adults with metastatic pancreatic ductal adenocarcinoma. The primary focus is on safety and tolerability by monitoring treatment-emergent adverse events from both the device and chemotherapy, with adherence to device use also recorded. Secondary assessments include signals of antitumor activity such as response rate and progression outcomes, and the protocol requires at least one liver metastasis accessible for biopsy. Participants wear noninvasive transducer arrays on the skin around the tumor region while receiving scheduled modFOLFIRINOX infusions.

Who should consider this trial

Good fit: Adults (≥18) with histologically confirmed metastatic pancreatic ductal adenocarcinoma, ECOG 0–1, at least one liver lesion suitable for biopsy, eligible for modFOLFIRINOX, and able to operate and wear the TTFields device are appropriate candidates.

Not a fit: Patients with ECOG ≥2, those who cannot tolerate modFOLFIRINOX, those without an accessible liver metastasis, or those unable or unwilling to wear the device are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, adding TTFields to modFOLFIRINOX could improve tumor control or survival without adding substantial systemic toxicity.

How similar studies have performed: TTFields have shown clinical benefit and regulatory approval in other cancers such as glioblastoma and mesothelioma, but evidence for pancreatic cancer is currently limited to early-phase or exploratory studies.

Eligibility criteria

Inclusion Criteria:

All the patients should comply with the following criteria for inclusion:

1. Histological/cytological diagnosis of pancreatic adenocarcinoma.
2. The patient should be 18 years of age and older.
3. The patient has given consent to participate in the study.
4. The patient should be able to comply with all the requirements of the clinical trial.
5. Life expectancy of at least 3 months.
6. Metastatic disease with, at least, one hepatic lesion that must be accessible for biopsy.
7. Measurable disease as defined by Response Evaluation Criteria in Solid Tumor v1.1 (RECIST 1.1) apart from the liver lesion to be biopsied.
8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
9. Amenable and assigned by the investigator to receive therapy with modFOLFIRINOX.
10. Prior chemotherapy or radiotherapy on the neoadjuvant or adjuvant setting is allowed as long as at least six months have elapsed since last chemotherapy treatment.
11. Able to operate the Novo TTF-200T System independently or with the help of a caregiver.
12. Adequate hematologic and organ function, defined by the following laboratory test results, obtained during the screening period and before C1D1.

    1. WBC higher than or equal to 2.5 x 10\^9/L.
    2. ANC higher than or equal to 1.5 x 10\^9/L without granulocyte colony-stimulating factor support.
    3. Platelet count higher than or equal to 100 x 10\^9/L without transfusion.
    4. Hemoglobin higher than or equal to 9 g/dL. Patients may be transfused to meet this criterion.
    5. Albumin higher than or equal to 2.5 g/dL.
    6. Serum bilirubin lower than or equal to 1.5 times the upper limit of normal (ULN); patients with known Gilbert´s disease may have a bilirubin value lower than or equal to 3 x ULN.
    7. INR and aPTT lower than or equal to 1.5 x ULN.
    8. AST, ALT, lower than or equal to 5 x ULN.
    9. Serum creatinine lower than or equal to 1.5 x ULN or Creatinine Clearance higher than or equal to 30ml/min (calculated using Cockcroft-Gault formula).
13. For women of childbearing potential: Negative serum pregnancy test within 14 days prior to C1D1. Agreement to remain abstinent (refrain from heterosexual intercourse) or use of contraceptive methods that result in a failure rate of lower than or equal to 1 percentage per year during the treatment period (combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal o transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable o implantable); intrauterine device (IUD) or intrauterine hormone-releasing system (IUS); bilateral tubal occlusion or vasectomized partner) and for at least 180 days after the last study treatment. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (higher than or equal to 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).

Exclusion Criteria:

Patients who present any of the following criteria for exclusion cannot be included in the clinical trial:

1. Malignancies other than pancreatic cancer within 3 years prior to Cycle 1 Day 1 (C1D1) with the exceptions of those with a negligible risk of metastasis or death (e.g., expected 5-year overall survival higher than 90 percentage), treated with expected curative outcome (such as but not limited to: adequately treated in situ carcinoma of the cervix, basal squamous or melanomatous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ of the breast treated surgically with curative intent).
2. Previous treatment with chemotherapy for metastatic pancreatic ductal adenocarcinoma.
3. Untreated CNS metastases. Treatment of brain metastases, either by surgical or radiation techniques, must have been completed at least 4 weeks prior to study entry.
4. Known dihydropyrimidine dehydrogenase deficiency or thymidylate synthase gene polymorphism predisposing the patient for 5-fluorouracil (5-FU) toxicity.
5. Previous radiation therapy within 14 days prior to C1D1 and/or persistence of radiation-related adverse effects.
6. Implantable electronic medical devices in the torso, such as pacemakers.
7. Known severe hypersensitivities to medical adhesives or hydrogel, or history of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study treatments used.
8. Spinal cord compression not definitively treated with surgery and/or radiation.
9. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
10. Pregnant and lactating women
11. Patients who have received brivudine, sorivudine or analogues 4 weeks prior to Fluoracile administration.
12. Serious co-morbidities, including but not limited to:

    1. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/third degree hart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse.
    2. History of cerebrovascular accident (CVA) within 3 months prior to randomization or that is not stable.
    3. Active infection or serious underlying medical condition that would impair the ability of the patient to receive protocol therapy.
    4. History of any psychiatric condition that might impair patient´s ability to understand or comply with the requirements of the study or to provide consent.

Where this trial is running

Pamplona, Navarre and 4 other locations

• Clínica Universidad de Navarra — Pamplona, Navarre, Spain (Recruiting)
• Hospital Universitario de Cruces — Barakaldo, Vizcaya, Spain (Not_yet_recruiting)
• Hospital de Galdakao — Galdakao, Vizcaya, Spain (Not_yet_recruiting)
• Fundación Jiménez-Díaz — Madrid, Spain (Not_yet_recruiting)
• Hospital Universitario de Araba — Vitoria-Gasteiz, Álava, Spain (Not_yet_recruiting)

Study contacts

• Principal investigator: Mariano Ponz Sarvisé, MD, PhD — Clínica Universidad de Navarra
• Study coordinator: Mariano Ponz Sarvisé, MD, PhD

Conditions Pancreatic Adenocarcinoma Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma